Pharmacodynamic Modeling of Cell Cycle Effects for Gemcitabine and Trabectedin Combinations in Pancreatic Cancer Cells
about
MEK inhibitors cobimetinib and trametinib, regressed a gemcitabine-resistant pancreatic-cancer patient-derived orthotopic xenograft (PDOX)Depletion of tumor-associated macrophages switches the epigenetic profile of pancreatic cancer infiltrating T cells and restores their anti-tumor phenotype.Silencing of ATF2 inhibits growth of pancreatic cancer cells and enhances sensitivity to chemotherapy.Mechanism-Based Disease Progression Model Describing Host-Pathogen Interactions During the Pathogenesis of Acinetobacter baumannii PneumoniaThymoquinone synergizes gemcitabine anti-breast cancer activity via modulating its apoptotic and autophagic activities
P2860
Pharmacodynamic Modeling of Cell Cycle Effects for Gemcitabine and Trabectedin Combinations in Pancreatic Cancer Cells
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年学术文章
@wuu
2016年学术文章
@zh-cn
2016年学术文章
@zh-hans
2016年学术文章
@zh-my
2016年学术文章
@zh-sg
2016年學術文章
@yue
2016年學術文章
@zh
2016年學術文章
@zh-hant
name
Pharmacodynamic Modeling of Ce ...... ons in Pancreatic Cancer Cells
@en
Pharmacodynamic Modeling of Ce ...... ns in Pancreatic Cancer Cells.
@nl
type
label
Pharmacodynamic Modeling of Ce ...... ons in Pancreatic Cancer Cells
@en
Pharmacodynamic Modeling of Ce ...... ns in Pancreatic Cancer Cells.
@nl
prefLabel
Pharmacodynamic Modeling of Ce ...... ons in Pancreatic Cancer Cells
@en
Pharmacodynamic Modeling of Ce ...... ns in Pancreatic Cancer Cells.
@nl
P2093
P2860
P356
P1476
Pharmacodynamic Modeling of Ce ...... ons in Pancreatic Cancer Cells
@en
P2093
Gilbert Koch
Robert M Straubinger
Sihem Ait-Oudhia
William J Jusko
P2860
P356
10.3389/FPHAR.2016.00421
P577
2016-11-15T00:00:00Z